Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells
Miersch, S.; Ustav, M.; Li, Z.; Case, J. B.; Ganaie, S.; Matusali, G.; Colavita, F.; Lapa, D.; Capobianchi, M. R.; Novelli, G.; Gupta, J. B.; Jain, S.; Pandolfi, P. P.; Diamond, M. S.; Amarasinghe, G.; Rini, J. M.; Sidhu, S. S.
Show abstract
Coronaviruses (CoV) are a large family of enveloped, RNA viruses that circulate in mammals and birds. Three highly pathogenic strains have caused zoonotic infections in humans that result in severe respiratory syndromes including the Middle East Respiratory Syndrome CoV (MERS), Severe Acute Respiratory Syndrome CoV (SARS), and the ongoing Coronavirus Disease 2019 (COVID-19) pandemic. Here, we describe a panel of synthetic monoclonal antibodies, built on a human IgG framework, that bind to the spike protein of SARS-CoV-2 (the causative agent of COVID-19), compete for ACE2 binding, and potently inhibit SARS-CoV-2. All antibodies that exhibited neutralization potencies at sub-nanomolar concentrations against SARS-CoV-2/USA/WA1 in Vero E6 cells, also bound to the receptor binding domain (RBD), suggesting competition for the host receptor ACE2. These antibodies represent strong immunotherapeutic candidates for treatment of COVID-19.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Doxycycline inhibition of a pseudotyped virus transduction does not translate to inhibition of SARS-CoV-2 infectivity 95%
- Receptor binding domain (RBD) antibodies contribute more to SARS-CoV-2 neutralization when target cells express high levels of ACE2 95%
- In silico, in vitro and in cellulo models for monitoring SARS-CoV-2 spike/human ACE2 complex, viral entry and cell fusion 95%
Similar papers in this journal
- Design of a Streptococcus pyogenes M protein immunogen to elicit M type cross-reactivity 95%
- The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization 94%
- Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment 94%
Similar papers in this journal
- SARS-CoV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection 96%
- Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2 95%
- Expression and purification of human neutrophil proteinase 3 from insect cells and characterization of ligand binding 95%
Similar papers in this journal
- Activity of EGFR transmembrane region variants indicates specific transmembrane dimers are not required for EGFR activity 93%
- Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp12/7/8 RNA-dependent RNA Polymerase 93%
- Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp13 Helicase 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.